secwatch.observer — SEC 8-K summary
======================================

Issuer:     HERON THERAPEUTICS, INC. /DE/ (HRTX)
CIK:        0000818033
Form:       8-K
Filed at:   2021-09-24T23:59:59+00:00
Accession:  0001564590-21-048772
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Heron Therapeutics appoints two new independent directors to board
------------------------------------------------------------------

- Sharmila Dissanaike, M.D. appointed to board effective Sept 20, 2021; she is a trauma surgeon and University Distinguished Professor at Texas Tech.
- Susan Rodriguez appointed to board effective same date; she is Chief Commercial Officer of Ardelyx and has 25+ years biopharma experience.
- Both directors will serve initial term until 2022 Annual Meeting; initial equity awards: 37,500 options and 6,250 RSUs each.
- Both qualify as independent under Nasdaq rules; not immediately assigned to any Board committees.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818033/000156459021048772/0001564590-21-048772-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818033/000156459021048772/hrtx-8k_20210920.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-048772

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer